Medical Advocates

KP1461
 
Main Page

New and Noteworthy
Journal Abstracts, Papers, and Commentaries

 



 


 


ARV Investigational  Drugs Main Page Home Page        

Last Update:  March 11, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
 

June 2012
 

Journal Papers, Abstracts, and Commentaries
 

 
Safety, Tolerability and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV-1-Infected Subjects.
Hicks C, Clay P, Redfield RR, et al
AIDS Res Hum Retroviruses
. 2012 Jun 28

Abstract
 
Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults.
Clay PG, McRae M, Laurent JP.
J Int Assoc Physicians AIDS Care (Chic).
Abstract

FULL-TEXT ARTICLE
Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside
KP1461.
Mullins JI, Heath L, Hughes J
PLoS One
. 2011 Jan 14;6(1):e15135.
Paper
 

  New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.
Becker S.

AIDS Treat News
. 2007 Jul-Sep;(423):3-7.
Abstract
 
  KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
Harris KS, Brabant W, Styrchak S, et al

Antiviral Res
. 2005 Jul;67(1):1-9
Abstract
   

 


Conference Reports, Abstracts,  and Posters
     

 


ARV Investigational  Drugs Main Page Home Page        

KP1461